April 5, 2025 06:00 AM EDT
Weekly

Staff cuts sweep across FDA; Tar­iff roll­out rais­es ques­tions; The R&D 15 is back; and more

Nicole DeFeudis

Editor

Max Gelman

Senior Editor

Wel­come back to End­points Week­ly! Much of this week’s head­lines dealt with the fall­out of cuts at the FDA and across HHS, no­tably in­clud­ing the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Q&A: David Liu talks about sci­ence un­der pres­sure, teas­es “dis­ease-ag­nos­tic” gene edit­ing

Q&A: A con­ver­sa­tion with GLP-1 co-dis­cov­er­er Jens Ju­ul Holst on the fu­ture of in­cretin-based drugs

Marks was asked to pro­vide non-ex­is­tent vac­cine risk da­ta: WSJ

Trump ad­min­is­tra­tion leaves obe­si­ty cov­er­age ex­pan­sion out of new Medicare rule

Se­cre­tive Chi­nese start­up be­gins first-ever clin­i­cal tri­al of cir­cu­lar RNA ther­a­py

sponsored

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

A service from the Financial Times